Relay Therapeutics, Inc.
General ticker "RLAY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $650.2M (TTM average)
Relay Therapeutics, Inc. follows the US Stock Market performance with the rate: 56.1%.
Estimated limits based on current volatility of 3.8%: low 7.49$, high 8.09$
Factors to consider:
- Total employees count: 261 (-19.2%) as of 2024
- Top business risk factors: Market competition, Operational and conduct risks, Geopolitical risks, Regulatory and compliance, Cybersecurity threats
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.77$, 7.43$]
- 2025-12-31 to 2026-12-31 estimated range: [2.46$, 6.59$]
Financial Metrics affecting the RLAY estimates:
- Positive: with PPE of -1.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -40.97 <= 0.33
- Positive: Shareholder equity ratio, % of 89.27 > 63.39
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of -43.42 <= -0.75
- Positive: -14.38 < Investing cash flow per share per price, % of -6.76
Short-term RLAY quotes
Long-term RLAY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.38MM | $25.55MM | $10.01MM |
| Operating Expenses | $300.66MM | $398.55MM | $382.48MM |
| Operating Income | $-299.27MM | $-373.00MM | $-372.47MM |
| Non-Operating Income | $8.77MM | $31.03MM | $34.76MM |
| R&D Expense | $246.35MM | $330.02MM | $319.09MM |
| Income(Loss) | $-290.51MM | $-341.97MM | $-337.71MM |
| Profit(Loss)* | $-290.51MM | $-341.97MM | $-337.71MM |
| Stockholders Equity | $950.22MM | $752.00MM | $777.79MM |
| Inventory | $12.11MM | $0.00MM | $0.00MM |
| Assets | $1,099.77MM | $843.98MM | $871.30MM |
| Operating Cash Flow | $-229.49MM | $-300.32MM | $-249.11MM |
| Capital expenditure | $9.06MM | $4.13MM | $2.02MM |
| Investing Cash Flow | $-188.75MM | $257.63MM | $-41.08MM |
| Financing Cash Flow | $289.91MM | $34.75MM | $270.15MM |
| Earnings Per Share** | $-2.59 | $-2.79 | $-2.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.